CBP-307

DRUG3 trials

Sponsors

Connect Biopharm LLC, Connect Biopharma Australia Pty Ltd

Conditions

Autoimmune DiseasesHealthy Adult Subjects

Phase 1

Phase 1 Study Accessing the Safety and Tolerability of CBP-307

CompletedNCT02280434

Connect Biopharm LLCAutoimmune Diseases

Start: 2014-11-30End: 2015-08-31Target: 64Updated: 2016-11-03

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

CompletedNCT04818229

Connect Biopharma Australia Pty LtdAutoimmune Diseases

Start: 2021-06-01End: 2022-03-30Updated: 2024-11-04

A Study On Human Mass Balance And Biotransformation

CompletedNCT05040113

Connect Biopharm LLCHealthy Adult Subjects

Start: 2021-09-04End: 2021-10-30Updated: 2022-04-05

Related Papers

Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia

Frontiers in Immunology2024-06-173 citations